Using an Economic Model to Choose Initial Appropriate Antibiotic Therapy Based on Differences in In-Vitro Susceptibility to Ceftolozane/Tazobactam and Piperacillin/Tazobactam

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.09.1680
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy